TEVA Teva Pharmaceutical Industries Ltd
Price Chart
Executive Summary
Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's disease chorea led to patient-reported improvements in movement and quality of life, with 74% of patients reporting improvement and over 85% reporting better daily activities and social life. The data reinforces the drug's clinical value but does not provide new financial figures, regulatory decisions, or guidance changes.
Actionable Insight
The data is clinically supportive but does not change Teva's near-term financial outlook. Monitor for any future label expansion or competitive dynamics in the HD chorea market, but no immediate trading catalyst from this release.
Key Facts
- Data from a real-world, decentralized study on HD chorea patients treated with AUSTEDO/AUSTEDO XR presented at the Advanced Therapeutics in Movement & Related Disorders Congress (June 4-8, 2026).
- 74% of patients reported improvement in chorea movements since initiating treatment (PGIC scale).
- Over 85% of patients reported improvements in goals related to daily activities and social life.
- 77% of caregivers reported improvements in goals related to their social life and emotional wellbeing.
- No new financial data, revenue, EPS, guidance, or regulatory action was disclosed in the press release.
Financial Impact
No financial figures provided; the press release is a clinical data update without revenue or earnings implications.
Risk Factors
- No new revenue or earnings data; the press release is purely clinical and does not alter financial expectations.
- Forward-looking statements about AUSTEDO commercialization are subject to competitive and regulatory risks.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307494 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
May 18, 2026
19d ago
|
Insider Cluster
| — | awaiting T+20 | — | — |
|
May 18, 2026
19d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 29, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 29, 2026
5w ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Apr 16, 2026
7w ago
|
Court Ruling
| $31.26 $36.25 | ▲ +15.98% | ▲ +10.16% | $34.19 (+9.39%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $28.70 $32.00 | ▲ +11.50% | ▲ +2.18% | $34.19 (+19.15%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $33.76 $28.33 | ▼ −16.09% | ▼ −8.15% | $34.19 (+1.29%) |
|
Feb 26, 2026
14w ago
|
Insider Cluster
| $33.75 $29.76 | ▲ +11.82% | ▲ +5.42% | $34.19 (−1.32%) |
|
Feb 26, 2026
14w ago
|
Insider Cluster
| $33.75 $29.76 | ▼ −11.82% | ▼ −5.42% | $34.19 (+1.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access